ChemBriefAmgen posts higher-than-expected third quarter results, but shares dip
Amgen reported third-quarter sales of $10.4 billion, beating expectations and raising its full-year outlook despite a share price dip driven by patent expirations and pipeline uncertainty regarding it
reuters · 2026-11-03 13:05